K. Schalper

R. Herbst, A. Chiang, D. Zelterman, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

K. Schalper, M. Javle, I. Roá, 2014, Gastrointestinal cancer research : GCR.

Connexin 43 hemichannels mediate the Ca2+ influx induced by extracellular alkalinization.

K. Schalper, J. Sáez, Helmuth A. Sánchez, 2010, American journal of physiology. Cell physiology.

Opening of connexin 43 hemichannels is increased by lowering intracellular redox potential

K. Schalper, M. Bennett, J. Sáez, 2007, Proceedings of the National Academy of Sciences.

RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.

L. Tanoue, R. Herbst, K. Schalper, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.

Tae Kon Kim, R. Herbst, K. Schalper, 2021, Cancer discovery.

Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies

K. Schalper, Miguel Lopez de Rodas, 2021, Nature Reviews Clinical Oncology.

P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC: Topic: IT

R. Herbst, A. Chiang, D. Zelterman, 2017 .

Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

K. Schalper, I. Datar, 2016, Clinical Cancer Research.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 (cid:1) / (cid:1) IL2R g null Immunode ﬁ cient Mice

M. Hidalgo, K. Schalper, I. Melero, 2015 .

Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer

D. Rimm, K. Schalper, A. Psyrri, 2021, Clinical Cancer Research.

Dysfunctions of the diffusional membrane pathways mediated by hemichannels in inherited and acquired human diseases.

K. Schalper, J. Sáez, J. Orellana, 2009, Current vascular pharmacology.

Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive rats

K. Schalper, E. Marusic, Mauricio Sandoval, 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Heterogenous presence of Neutrophil Extracellular Traps in human solid tumours is partially dependent on Interleukinâ•’8

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2021 .

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling

K. Schalper, K. Kannan, R. Gregory, 2022, Journal for ImmunoTherapy of Cancer.

Currently Used Methods for Identification and Characterization of Hemichannels

K. Schalper, J. Sáez, J. Orellana, 2008, Cell communication & adhesion.

Cation permeation through connexin 43 hemichannels is cooperative, competitive and saturable with parameters depending on the permeant species.

K. Schalper, M. Bennett, J. Sáez, 2011, Biochemical and biophysical research communications.

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

Immunodivergence in Metastatic Colorectal Cancer.

K. Schalper, I. Melero, C. D. de Andrea, 2018, Cancer cell.

Overexpression of the HER2/neu gene

K. Schalper, X. Aretxabala, M. Javle, 2014 .

Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

William R. Bradley, D. Rimm, K. Schalper, 2013, Archives of pathology & laboratory medicine.

p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival Lesions

K. Schalper, S. González, P. Zoroquiaín, 2012, International journal of surgical pathology.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

M. Hidalgo, K. Schalper, I. Melero, 2015, Cancer research.

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

Vamsidhar Velcheti, David L Rimm, Lajos Pusztai, 2014, Clinical Cancer Research.

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Hongyu Zhao, M. Carleton, K. Schalper, 2020, Nature Medicine.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2017, Cancer treatment reviews.

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

G. Zhu, K. Schalper, M. Sznol, 2019, Cell.

Effects of Radiation on the Tumor Microenvironment.

K. Schalper, S. Shiao, A. Monjazeb, 2020, Seminars in Radiation Oncology.

Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL‐8

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2021, The Journal of pathology.

Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

R. Herbst, D. Rimm, K. Politi, 2019, Clinical Cancer Research.

Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity

D. Schadendorf, B. Ueberheide, Ting Chen, 2021, Cancer Immunology Research.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

L. Pusztai, D. Rimm, K. Schalper, 2016, Breast Cancer Research.

Modulation of gap junction channels and hemichannels by growth factors.

K. Schalper, M. Bennett, J. Sáez, 2012, Molecular bioSystems.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2019, Nature Medicine.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?

I. Jacobs, K. Schalper, S. Potluri, 2019, Journal of Immunotherapy for Cancer.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

David L Rimm, Ludmila V. Danilova, Clifford Hoyt, 2019, JAMA oncology.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Immunotherapy for Cancer.

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

P. Ascierto, C. Gridelli, H. Zarour, 2018, Journal of Immunotherapy for Cancer.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

K. Syrigos, D. Rimm, K. Schalper, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.

K. Schalper, V. Velcheti, S. Mukhopadhyay, 2017, JCO precision oncology.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

R. Herbst, D. Rimm, K. Schalper, 2016, Clinical Cancer Research.

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research

R. Herbst, K. Schalper, E. Kaftan, 2016, Clinical Cancer Research.

Possible role of hemichannels in cancer

K. Schalper, M. Oyarzo, D. Carvajal-Hausdorf, 2014, Front. Physiol..

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

J. Sosman, K. Schalper, P. LoRusso, 2019, Pigment cell & melanoma research.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

R. Halaban, K. Schalper, M. Sznol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance

D. Rimm, K. Schalper, A. Santin, 2017, Gynecologic oncology.

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

Vamsidhar Velcheti, David L. Rimm, Kurt Schalper, 2013, PloS one.

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

D. Rimm, K. Schalper, K. Lu, 2014, Oncogene.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images

A. Madabhushi, Xiangxue Wang, K. Schalper, 2017, Scientific Reports.

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

I. Wistuba, M. Mino‐Kenudson, F. Hirsch, 2022 .

Programmed Cell Death 1 ( PD-1 ) Ligand ( PD-L 1 ) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1 / PD-L 1 Axis Inhibitors : A Systematic Review and Meta-Analysis

K. Schalper, V. Velcheti, S. Mukhopadhyay, 2017 .

Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.

Shuangge Ma, M. Krauthammer, Y. Kong, 2020, Biochemical pharmacology.

Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer

D. Rimm, Gang Han, K. Schalper, 2016, Modern Pathology.

EGFR‐GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma

K. Syrigos, D. Rimm, K. Schalper, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Microenvironment: Immune Effector and Suppressor Imbalance

K. Schalper, Kelsey B Sheehan, 2021, Lung Cancer.

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

D. Rimm, K. Schalper, V. Velcheti, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy

K. Schalper, I. Melero, P. Berraondo, 2020, Clinical Cancer Research.

Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer

D. Rimm, K. Schalper, K. Syrigos, 2021, Clinical Cancer Research.

Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry

D. Rimm, K. Schalper, V. Pelekanou, 2021, Clinical Cancer Research.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Y. Kluger, R. Herbst, A. Chiang, 2020, The Lancet. Oncology.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

S. Vesely, D. Longo, R. Isseroff, 2018, Nature Medicine.

Basic Overview of Current Immunotherapy Approaches in Cancer.

K. Schalper, V. Velcheti, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015, Journal of the National Cancer Institute.

Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry

Kelly P. Stanton, Ruth R. Montgomery, Y. Kluger, 2019, Clinical Cancer Research.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

R. Herbst, D. Rimm, S. Gettinger, 2019, Clinical Cancer Research.

Graph of graphs analysis for multiplexed data with application to imaging mass cytometry

Ronen Talmon, Yuval Kluger, Tal Shnitzer, 2020, bioRxiv.

Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

K. Schalper, M. Bennett, C. Giaume, 2009, Antioxidants & redox signaling.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

D. Rimm, K. Schalper, V. Velcheti, 2017, Journal of Immunotherapy for Cancer.

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases

K. Schalper, H. Kluger, J. Contessa, 2021, Journal for ImmunoTherapy of Cancer.

[Quality of DNA from archival pathological samples of gallbladder cancer].

K. Schalper, I. Roá, A. Game, 2013, Revista medica de Chile.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer

Dafydd G. Thomas, D. Rimm, K. Schalper, 2018, npj Breast Cancer.

Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing

Kisha Mitchell, D. Rimm, K. Schalper, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

L. Pusztai, D. Rimm, V. Bossuyt, 2014, Cancer Immunology Research.

Oncolytic virus immunotherapy: future prospects for oncology

S. Gettinger, K. Schalper, J. Ludwig, 2018, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer

K. Schalper, J. Frederick, R. Meehan, 2021, Clinical Cancer Research.

Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: Current insights

K. Schalper, V. Velcheti, V. Venur, 2014 .

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers

L. Pusztai, D. Rimm, K. Schalper, 2018, Breast Cancer Research.

Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015 .

Imaging , Diagnosis , Prognosis In Situ Tumor PD-L 1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

L. Pusztai, D. Rimm, K. Schalper, 2014 .

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer

R. Herbst, K. Syrigos, K. Schalper, 2017, Clinical Cancer Research.

The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.

D. Rimm, M. Hurwitz, K. Schalper, 2015 .

Overview of Lung Cancer Immunotherapy

K. Schalper, M. Sanmamed, I. Eguren-Santamaria, 2020, Cancer journal.

Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study

A. Madabhushi, Xiangxue Wang, Jun Xu, 2020, The Lancet. Digital health.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

L. Pusztai, D. Rimm, K. Schalper, 2015, Journal of the National Cancer Institute.

Connexin hemichannel composition determines the FGF-1-induced membrane permeability and free [Ca2+]i responses.

K. Schalper, J. Sáez, Agustín D. Martínez, 2008, Molecular biology of the cell.

Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.

R. Herbst, D. Rimm, S. Gettinger, 2017 .

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

R. Herbst, K. Syrigos, D. Rimm, 2017, Clinical Cancer Research.

Possible Involvement of Different Connexin43 Domains in Plasma Membrane Permeabilization Induced by Ischemia-Reperfusion

M. Bennett, K. Schalper, J. Sáez, 2007, Journal of Membrane Biology.

Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement

D. Rimm, K. Schalper, Daniel Carvajal, 2016, Laboratory Investigation.

Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.

K. Schalper, J. Miquel, F. Nervi, 2015, Annals of hepatology.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

Christos Hatzis, Lajos Pusztai, Kurt A. Schalper, 2016, Breast Cancer Research.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

PD-L 1 Expression Correlates with Tumor-In fi ltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

L. Pusztai, D. Rimm, V. Bossuyt, 2015 .

Regulation of intercellular calcium signaling through calcium interactions with connexin-based channels.

K. Schalper, J. Sáez, J. Orellana, 2012, Advances in experimental medicine and biology.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).

R. Herbst, D. Rimm, Joseph K. McLaughlin, 2014 .

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

A. Madabhushi, D. Rimm, K. Schalper, 2023, NPJ precision oncology.

[Primary cerebral lymphomatoid granulomatosis in a HIV-positive patient. Case report].

K. Schalper, J. Valbuena, 2011, Revista medica de Chile.

Immunologic Analysis Of Non-Small Cell Lung Cancer In People Living With Hiv

K. Schalper, K. Hysell, R. Yusuf, 2022 .

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

A. Chen, K. Schalper, J. Eder, 2023, Cancer research communications.

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

S. Buys, K. Schalper, P. LoRusso, 2020 .

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.

I. Wistuba, M. Mino‐Kenudson, F. Hirsch, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop

P. Ascierto, E. Puré, A. Ribas, 2023, Journal for ImmunoTherapy of Cancer.

MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)

R. Herbst, D. Zelterman, D. Rimm, 2017 .

PD-L1 expression and tumor-infiltrating lymphocytes

K. Schalper, 2014, Oncoimmunology.

Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

A. Madabhushi, D. Rimm, K. Schalper, 2019, Nature reviews. Clinical oncology.

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Y. Kong, J. Lacy, K. Schalper, 2023, Cancer research communications.

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy

K. Schalper, V. Velcheti, D. Schrump, 2023, Cell reports.

PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).

J. Bordeaux, D. Rimm, K. Schalper, 2018 .

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.

J. Riess, K. Schalper, S. Shiao, 2023, Nature communications.

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.

M. Kris, I. Wistuba, N. Altorki, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The β_1-adrenergic receptor links sympathetic nerves to T cell exhaustion

K. Schalper, S. Kaech, M. Heeg, 2023, Nature.